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The impact of KRAS mutations on cetuximab sensitivity in epidermal growth factor receptor fluorescence in situ hybridisation-positive
(EGFR FISHþ) metastatic colorectal cancer patients (mCRC) has not been previously investigated. In the present study, we analysed
KRAS, BRAF, PI3KCA, MET, and IGF1R in 85 mCRC treated with cetuximab-based therapy in whom EGFR status was known. KRAS
mutations (52.5%) negatively affected response only in EGFR FISHþ patients. EGFR FISHþ/KRAS mutated had a significantly lower
response rate (P¼0.04) than EGFR FISHþ/KRAS wild type patients. Four EGFR FISHþ patients with KRAS mutations responded to
cetuximab therapy. BRAF was mutated in 5.0% of patients and none responded to the therapy. PI3KCA mutations (17.7%) were not
associated to cetuximab sensitivity. Patients overexpressing IGF1R (74.3%) had significantly longer survival than patients with low
IGF1R expression (P¼0.006), with no difference in response rate. IGF1R gene amplification was not detected, and only two (2.6%)
patients, both responders, had MET gene amplification. In conclusion, KRAS mutations are associated with cetuximab failure in EGFR
FISHþ mCRC, even if it does not preclude response. The rarity of MET and IGF1R gene amplification suggests a marginal role in
primary resistance. The potential prognostic implication of IGF1R expression merits further evaluation.
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With about 400000 cases each year, colorectal cancer (CRC) is one
of the most common human malignancies and one of the leading
causes of cancer-related death in the western world (Jemal et al,
2007). During the last decade, median duration of survival among
patients with metastatic CRC (mCRC) has increased from 12 to 21
months, mainly because of the introduction of new cytotoxic
agents such as oxaliplatin and irinotecan (De Gramont et al, 2000;
Douillard et al, 2000).
Improvements in the knowledge of cancer biology has led to the
development of agents that specifically inhibit tumour growth. The
epidermal growth factor receptor (EGFR) is often upregulated in
CRC, and monoclonal antibodies represent one of the most
important options to inhibit such a target. Cetuximab (Erbitux,
Merck, Lyon, France), a monoclonal antibody interfering with the
extracellular domain of EGFR, has proven to be active in EGFR
expressing CRC in whom other treatments have failed (Jonker
et al, 2007). However, only a small proportion of patients (o20%)
achieve an objective response, and tumour shrinkage is not
confined to patients with high level of EGFR protein expression
determined by immunohistochemistry (IHC, Chung et al, 2005).
Recently, several studies provided relevant insights on mecha-
nisms underlying cetuximab sensitivity. Retrospective analyses
showed that tumour regression is more frequently observed among
patients with increased EGFR gene copy number (Moroni et al,
2005; Sartore-Bianchi et al, 2007; Cappuzzo et al, 2008), while lack
of response and short survival was observed in individuals
harbouring a KRAS mutation (Lie `vre et al, 2006, 2008; Di Fiore
et al, 2007; Khambata-Ford et al, 2007; Amado et al, 2008;
De Roock et al, 2008). Nevertheless, the incidence of KRAS
mutations in CRC cannot account for all resistant cases (Bamford
et al, 2004), and a consistent proportion of patients with increased
EGFR gene copy number does not respond to the therapy (Sartore-
Bianchi et al, 2007; Cappuzzo et al, 2008). For instance, in our
previous experience (Cappuzzo et al, 2008), disease progression
was observed in 39.5% of patients with EGFR gene gain detected by
fluorescence in situ hybridisation (EGFR FISHþ).
Several preclinical findings suggest that MET, the hepatocyte
growth factor receptor, could interfere with anti-EGFR strategies.
MET is a tyrosine kinase receptor (RTK) involved in cellular
proliferation and apoptosis (Jiang et al, 1999). Activation of MET
may lead to the activation of pathways downstream of Ras
(Graziani et al, 1991; Halaban et al, 1992; Rodriguez-Viciana et al,
1994), such as the Raf/MEK/mitogen-activated protein kinase
(MAPK) and the phosphatidylinositol 3-kinase (PI3K)/protein
kinase B pathway (PKB). In addition, MET is able to directly
activate PI3K/PKB pathway in a Ras independent manner
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s(Ponzetto et al, 1993). Concomitant RTK upregulation including
MET is common in human carcinomas with high frequency of
KRAS mutations, including colorectal cancer (Long et al, 2003).
Moreover, studies in lung cancer have shown that MET gene
amplification is responsible for acquired resistance to EGFR-
tyrosine kinase inhibitors (Engelman et al, 2007).
The insulin-like growth factor receptor 1 (IGF1R) is a tetrameric
transmembrane RTK implicated in promoting oncogenic trans-
formation, growth, and survival of cancer cells (Baserga et al, 1997;
Blakesley et al, 1997; Dufourny et al, 1997; Khandwala et al, 2000).
IGF1R activation triggers a cascade of reactions involving the Raf/
MEK/MAPK and the PI3K/PKB pathways (LeRoith et al, 1995;
Jones and Clemmons, 1995). Data on glioblastoma cell lines
suggested that IGF1R mediates resistance to anti-EGFR therapy
through continued activation of the PI3K-AKT pathway (Chakravarti
et al, 2002). IGF1R results in upregulation in the majority of CRC,
most likely contributing to the aggressive growth characteristics of
these tumours and poor prognosis (Hakam et al, 1999; Weber et al,
2002).
The impact of KRAS mutations on cetuximab sensitivity in
EGFR FISHþ patients has not been previously investigated.
Moreover, no clinical data exist on whether MET or IGF1R gene
gain could interfere with cetuximab sensitivity. On the basis of
these premises, we decided to conduct a study exploring the
impact of different biomarkers, including KRAS, MET and IGF1R,
on primary resistance to cetuximab therapy in metastatic,
chemorefractory, and CRC with known EGFR FISH status.
MATERIALS AND METHODS
Patient selection
The present study was conducted in a cohort of 85 chemore-
fractory, mCRC patients exposed to cetuximab-based therapy and
previously evaluated for EGFR by FISH (Cappuzzo et al, 2008).
Briefly, in our previous experience, patients were selected based on
two main criteria: presence of at least one measurable lesion and
availability of tumour tissue. No other clinical or biological
criterion was used for patient selection. Cetuximab was given to
each patient at the initial dose of 400mg per square meter,
followed by weekly infusion of 250mg per square meter. In all
patients, disease assessment was performed every 2 months, with a
confirmatory evaluation no less than 4 weeks after the response
assessment, according to the RECIST criteria (Therasse et al,
2000). The whole study population included 85 patients all
pretreated with chemotherapy, including irinotecan (83.5%) and/
or oxaliplatin (84.7%). The majority of patients were male (63.5%)
with a performance status of 0–1 (96.5%), and with a median age
of 63.2 years, with a primitive tumour in colon (76.5%) or rectum
(23.5%). EGFR was assessed by FISH in tumour samples from
primary tumour (43 cases), from metastasis (20 cases) or both
primary tumour and corresponding metastasis (22 cases). A mean
X2.92 EGFR gene copy number qualified the sample as EGFR
FISHþ. Among the 85 evaluable patients, 43 (50.6%) were EGFR
FISHþ and 42 (49.4%) were EGFR FISH . Cetuximab therapy
produced a significantly higher response rate (RR, 32.5 vs 2.3%,
Po0.0001) and a significantly longer time to progression (TTP, 6.6
vs 3.5 months, P¼0.02) in EGFR FISHþ than in EGFR FISH 
patients. The study was approved by the local Ethics Committee
and was conducted in accordance with ethical principles stated in
the most recent version of the Declaration of Helsinki.
Tissue preparation and IHC analysis
Sections from paraffin-embedded tissue blocks containing repre-
sentative malignant cells obtained at time of diagnosis were used
for this analysis. Sections were stained with antibodies against
IGF1R (Novus Biologicals, Littleton, CO, USA) according to the
manufacturer’s recommended protocols. Briefly, 4mm-thick tissue
sections were placed on glass slides and deparaffinised. The tissue
sections were incubated in 1mM EDTA (pH 8) for 40min at 981C
to unmask the antigens. The sections were then incubated with
IGF1R mouse antibody (1:50 diluted in phosphate buffer).
Immunohistochemical staining was performed at the Pathology
Department of Istituto Clinico Humanitas, Italy and slides were
interpreted independently by two pathologists (CL and LDT) who
were blinded to all patient information. As previously described
for IGF1R in lung cancer (Cappuzzo et al, 2006), a semiquanti-
tative approach was used to generate a score for each tissue core.
The percentage of stained cells (0–100%) was multiplied by the
dominant intensity pattern of staining, considering one as negative
or trace, two as weak, three as moderate and four as strong.
Therefore, the overall score ranged from 0 to 400.
FISH analyses
Blank tumour sections were submitted to dual-colour FISH assays
using in-house developed IGF1R/CEP15 and MET/CEN7 probe
cocktails on separate slides for each patient. The assays were
performed according to standard laboratory protocol. Initially the
slides were incubated for 2h – overnight at 651C, deparaffinised in
Citro-Solv (Fisher) and washed in 100% ethanol for 5min. The
slides were incubated in 2XSSC at 751C for 6–22min and digested
in 0.25mgml
 1 Proteinase K/2XSSC at 451C for 6–25min. Then,
the slides were washed in 2XSSC for 5min and dehydrated in
ethanol. Probes were applied to the selected hybridisation areas
(150–300ng of labelled DNA for each specimen), which were
covered with glass coverslips and sealed with rubber cement. DNA
denaturation was performed for 15min at 801C and the slides were
incubated at 371C for 40–48h.
Posthybridisation washes were performed with 2XSSC/0.3% NP-
40 at 721C for 2min. Then, the slides were washed in 2XSSC for
1min and dehydrated in ethanol. Chromatin was counterstained
with DAPI (0.3mgml
 1 in Vectashield, Vector Laboratories).
Analysis was performed on epifluorescence microscopes using
single interference filter sets for green (FITC), red (Texas red),
aqua (Aqua) and blue (DAPI) as well as dual (red/green) and triple
(blue, red, green) band pass filters. Each specimen was evaluated in
eight different tumour foci with 10 cells analysed in each area (total
of 80 cells per specimen).
Mutation analyses
Additional biomarkers analysed in the present study included
KRAS, BRAF, PI3KCA, and AKT. Mutations in KRAS (exons 1 and
2), BRAF (exons 11 and 15), PIK3CA (exons 9 and 20) and AKT
(exon 3) were examined using a previously published DNA
endonuclease (Surveyort) based method (Ja ¨nne et al, 2006). Exon-
specific PCR amplification was carried out for each of the indicated
genes, the resulting DNA products were subjected to Surveyort
digestion and analysed using the Transgenomic WAVE HS system
as previously described (Ja ¨nne et al, 2006). All mutations were
independently confirmed. PCR primers and conditions are
available upon request.
Statistical analyses
Statistical analyses were conducted using biomarker results
obtained on primary tumours, except in 20 cases where only
tissue from metastasis was available. The primary end point of the
study was the identification of biomarkers potentially associated
with progression of disease under cetuximab therapy. Analysis of
ROC (receiver operating characteristic) curve was carried out with
the aim of determining a cutoff point for MET and IGF1R
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sexpression or gene copy numbers as a continuous variable (Cai
and Moskowitz, 2004). Sensitivity and specificity were expressed in
terms of percentage and the value for which sensitivity and
sensibility were the highest has been chosen as the best cutoff
point. Secondary end points were association with TTP and overall
survival (OS). TTP was calculated from the time of first cetuximab
infusion to time of disease progression or last disease assessment.
OS was calculated from the time of first cetuximab infusion to
patient death or last contact.
Differences in response rate were compared by Fisher’s exact
test or w
2 test. TTP, OS and the 95% confidence intervals were
evaluated by survival analysis using Kaplan–Meier method
(Kaplan and Meier, 1985). TTP and OS for the groups with
negative and positive biomarker were compared using the log-rank
test. Statistical significance was set at o0.05 for each analysis. All
statistical analyses were performed using SPSS version 11.5.1 (SPSS
Italia srl, Bologna, Italy).
RESULTS
MET analysis
MET FISH analysis was successfully performed in 76 patients
(Table 1). Receiver operating characteristic curve analysis was
performed to identify the MET copy number cutoff that better
discriminates a resistant population but no association was found
with drug sensitivity. MET increased gene copy numbers (MET
FISHþ) were then defined as mean X5 per cell, which was
observed in seven patients (9.2%), including two (2.6%) with gene
amplification and five (6.6%) with high polysomy. Interestingly, all
MET FISHþ cases were also EGFR FISHþ, and such association
was statistically significant (P¼0.006). Nevertheless, MET FISHþ
status was not associated with resistance to cetuximab therapy,
and no difference in progressive disease rate was observed between
EGFR FISHþ/MET FISHþ and EGFR FISHþ/MET FISH  (42.8
vs 37.5%, P¼0.7).
IGF1R analyses
IGF1R was successfully analysed by FISH in 77 cases and by IHC in
70 cases. In the gene copy number evaluation, ROC analysis did
not identify a cutoff discriminating sensitive vs resistant patient
populations and no mCRC had mean 45 copies per cell to be
called IGF1R FISHþ. The mean IGF1R copy number ranged from
1.43 to 4.88 among the investigated mCRC. IGF1R gene copy
number was not associated with IGF1R IHC expression (Pearson
correlation coefficient 0.034, P¼0.7). As shown in Figure 1A, the
ROC analysis found an IGF1R IHC value of 95 associated with a
sensitivity of 90% (CI: 71.4–100) and a specificity of 28.3% (CI:
16.9–39.7). Using this cutoff, 18 patients (25.7%) resulted negative
and 52 (74.3%) positive (Table 2). Although response rate and TTP
were not significantly different in the two groups, IGF1R IHCþ
patients had a significantly longer survival than IGF1R IHC  (16.1
vs 6.7 months, P¼0.006), as shown in Figure 1B. No difference in
progressive disease rate was observed in EGFR FISHþ/IGF1R
IHCþ (N¼26) vs EGFR FISHþ/IGF1R IHC  (N¼9; 42.3 vs
44.4%, P¼0.9).
Mutation analyses
KRAS analysis was successfully performed in 80 cases, and 42
patients (52.5%). harboured a mutation, with G13D as the most
frequent mutation type (eight cases, 10.0%). Such mutations were
not associated with clinical or biological characteristics and
occurred in 22 EGFR FISHþ patients (53.7%). As illustrated in
Table 3, response rate significantly favoured patients with KRAS
wildtype (P¼0.048), as well as TTP and OS, although these
differences were not statistically significant (P¼0.2 and 0.3,
respectively).
BRAF was analysed in 79 cases, and only four patients (5.1%)
harboured a mutation (V599E). BRAF and KRAS mutations were
mutually exclusive. Owing to the low number of patients carrying a
BRAF mutation the statistical power was not enough to detect
difference in outcome. Nevertheless, none of the four BRAF-
mutated patients responded to cetuximab therapy, and TTP and
Table 1 Association of MET gene copy number with outcome to cetuximab therapy and patient biomarker status
Total (N/%) MET FISH+ (N/%) MET FISH  (N/%) P-value
Total evaluated 76 7 69
Progressive disease 38/50.0 3/42.8 35/50.7 0.7
Complete+partial+stable disease 38/50.0 4/57.2 34/49.3
Evaluated for EGFR Copy number 76 7 69
EGFR FISH+ 39/51.3 7/100 32/46.3 0.006
EGFR FISH  37/48.7 0 37/53.7
Evaluated for KRAS mutation 75 6 69
KRAS mutated 40/53.3 2/28.5 38/55.1 0.3
KRAS wild type 35/46.7 4/57.2 31/44.9
Evaluated for IGF1R expression 63 6 57
IGF1R IHC+ 48/76.1 4/66.6 44/77.1 0.5
IGF1R IHC  15/23.9 2/33.4 13/22.9
A mean X5 MET gene copy number qualified the sample as MET FISH positive. A mean X2.92 EGFR gene copy number qualified the sample as EGFR FISH positive. Among the
76 patients evaluated for MET, all were evaluated for EGFR FISH, 75 were evaluated for presence of KRAS mutations, and 63 for IGF1R expression.
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Figure 1 (A) ROC analysis identified an IGF1R value of 95 associated
with a sensitivity of 90% (CI: 71.4–100) and a specificity of 28.3% (CI:
16.9–39.7). (B) Patients IGF1R positive (scoreX95) had a median survival
of 16.1 months vs 6.7 months in IGF1R negative patients (P¼0.006).
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sOS resulted shorter than in BRAF wild-type individuals (TTP: 1.2
vs 5.4 months, P¼0.09; OS: 5.4 vs 9.8 months, P¼0.3).
A total of 79 patients were analysed for PI3KCA mutations. The
gene was mutated in 14 (17.7%) cases, with H1047 as the most
frequent mutation type (seven cases, 8.8%). No difference in
response rate, TTP or OS was observed in patients harbouring a
PI3KCA mutation vs wild type individuals. No AKT mutation was
identified among the 82 patients evaluated for this gene.
Outcome according to mutation and EGFR FISH status
To determine the relevance of KRAS or BRAF mutation in the
presence or absence of the drug target (EGFR), we analysed the
outcome of patients according to EGFR FISH status (Table 4).
KRAS mutations did not impact the outcome of EGFR FISH 
patients. No difference in response rate (5.3 vs 0%, P¼0.4), TTP
(3.2 vs 3.5 months, P¼1) and OS (10.8 vs 7.8 months, P¼0.5) was
observed in EGFR FISH /KRAS wild type vs EGFR FISH /KRAS
mutated. Conversely, EGFR FISHþ/KRAS mutated had a signi-
ficantly lower response rate (18.2 vs 47.7%, P¼0.04) and shorter
TTP (5.3 vs 7.4 months, P¼0.2) than EGFR FISHþ/KRAS wild-
type patients. Interestingly, four EGFR FISHþ patients with KRAS
mutations (G12V in one case, G12D in another one, G13D in
the remaining two cases) responded to cetuximab therapy.
These patients had a mean EGFR gene copy number ranging from
3.03 to 4.03.
Table 2 Association of IGF1R expression with patient biomarker status and outcome to cetuximab therapy
N/% IGF1R IHC+ (N/%) IGF1R IHC  (N/%) P-value
Total evaluated 70 52 18
Progressive disease 35/50.0 24/46.2 11/61.1 0.27
Complete+partial+stable disease 35/50.0 28/53.8 7/38.9
Evaluated for EGFR copy number 70 52 18
EGFR FISH+ 35/50.0 26/50.0 9/50.0 1.0
EGFR FISH  35/50.0 26/50.0 9/50.0
Evaluated for KRAS mutation 67 51 16
KRAS mutated 33/47.1 27/51.9 6/33.3 0.28
KRAS wild type 34/48.5 24/46.1 10/55.5
Evaluated for MET copy number 63 48 15
MET FISH+ 6/8.5 4/7.6 2/11.1 0.5
MET FISH  57/81.4 44/84.6 13/72.2
Using an ROC analysis, a score X95 qualified the tumour as IGF1R positive. A mean X5 MET gene copy number qualified the sample as MET FISH positive. A mean X2.92
EGFR gene copy number qualified the sample as EGFR FISH positive. Among the 70 patients evaluated for IGF1R, all were evaluated for EGFR FISH, 67 for KRAS mutations, and
63 for MET gene copy number.
Table 3 KRAS, BRAF, and PI3KCA mutations and outcome to cetuximab therapy
Genes Total Response rate (N/%) Time to progression (months) Survival (months)
KRAS evaluated 80
KRAS mutated 42 4/9.5 4.4 9.5
KRAS wild type 38 10/26.3 5.4 10.8
P-value 0.048 0.2 0.3
BRAF evaluated 79
BRAF mutated 4 0 1.2 5.4
BRAF wild type 75 13/17.3 4.6 9.8
P-value 0.3 0.09 0.3
PI3KCA evaluated 79
PI3KCA mutated 14 4/28.6 6.3 9.5
PI3KCA wild type 65 9/13.8 4.6 9.8
P-value 0.2 0.2 0.7
Table 4 Outcome of patients with KRAS or BRAF mutations stratified according to EGFR FISH status
Total Response rate (N/%) Time to progression (months) Survival (months)
EGFR FISH+/KRAS+ 22 4/18.2 5.3 13.8
EGFR FISH+/KRAS  19 9/47.4 7.4 9.8
P-value 0.04 0.2 0.3
EGFR FISH /KRAS+ 20 0 3.5 7.8
EGFR FISH /KRAS  19 1/5.3 3.2 10.8
P-value 0.4 1.0 0.5
EGFR FISH+/KRAS+ or BRAF+ 24 4/16.7 5.4 9.5
EGFR FISH+/KRAS  and BRAF  16 8/50.0 7.8 17.9
P-value 0.03 0.1 0.1
EGFR FISH /KRAS+ or BRAF+ 22 0 3.4 7.8
EGFR FISH /KRAS  and BRAF  17 1/5.9 3.8 10.8
P-value 0.4 0.5 0.5
KRAS+: Presence of mutation; KRAS : No mutation found. BRAF+: Presence of mutation; BRAF : No mutation found.
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patients with KRAS or BRAF mutation. No difference in cetuximab
sensitivity were observed in EGFR FISH  irrespective of KRAS and
BRAF status, while significantly lower response rate (16.7 vs 50.0%,
P¼0.037), shorter TTP (5.4 vs 7.8 months, P¼0.12) and shorter
OS (9.5 vs 17.9 months, P¼0.13) was observed in EGFR FISHþ/
KRAS or BRAF mutated vs EGFR FISHþ/KRAS or BRAF wild type.
DISCUSSION
In the present study, the first conducted in a mCRC population
with known EGFR status, we showed that KRAS mutation is
significantly associated with cetuximab failure in EGFR FISHþ
patients, even if it does not preclude response. Although
preclinical data supported the negative impact of MET, IGF1R,
and PI3KCA on cetuximab activity, in our study none of them
demonstrated a clinical relevance as predictors for primary
resistance, irrespective of the EGFR FISH result.
Previous studies demonstrated that KRAS mutations represent
the most relevant mechanism responsible for anti-EGFR strategy
failure (Lie `vre et al, 2006, 2008; Di Fiore et al, 2007; Khambata-
Ford et al, 2007; Amado et al, 2008; De Roock et al, 2008).
Nevertheless, in CRC no data existed whether KRAS mutations
drove cetuximab resistance in a patient population potentially
sensitive to anti-EGFR agents, neither whether such events
occurred in EGFR FISHþ individuals. In the present study, we
observed that the incidence of KRAS mutation was similar in EGFR
FISHþ and FISH  subgroups, indicating that these phenomena
are not mutually exclusive. It is noteworthy that no difference in
outcome was observed in the group of patients EGFR FISH 
irrespective of KRAS status, while the difference in response was
significant only in EGFR FISHþ. These results suggest that the
drug maybe ineffective in absence of the target, while KRAS
activation is able to drive drug resistance even if EGFR is present.
Interestingly, in our population of KRAS mutated patients, four
individuals responded to the therapy, and all were EGFR FISH
positive. This finding raises the possibility that, in presence of an
overexpressed target, occasionally tumour shrinkage could occur
also in individuals harbouring the mutation.
BRAF mutations were identified in 66% of melanomas, and in
smaller percentage in other human cancers including colorectal
(Davies et al, 2002). Our study confirmed that such mutation is not
frequent in CRC and could represent an additional mechanism
responsible for cetuximab failure. None of the patients carrying
BRAF mutation responded to the therapy, with a trend for shorter
TTP and survival, differences not significant probably because of
the small number of patients.
A recent study showed that colorectal cancer cell lines with
activating PI3KCA mutations or with loss of PTEN expression were
more resistant to cetuximab therapy than PI3KCA wild type/PTEN
expressing cell lines (Jhawer et al, 2008). Importantly, simulta-
neous mutations of KRAS and PI3KCA conferred maximal
resistance to cetuximab. In our study, combination of multiple
mutation tests (KRAS or BRAF±PI3KCA) did not provide addi-
tional information over a single mutation test (data not shown).
Previous studies have investigated MET in CRC with semi-
quantitative techniques such as immunoblotting or IHC (Di Renzo
et al, 1995; Hiscox et al, 1997; Fujita and Sugano, 1997; Fukuura
et al, 1998). Our study represents the first report in CRC assessing
MET at the genomic level using FISH. We report here that MET
amplification is a rare event in CRC, occurring in about 2% of
cases. Only two patients had MET amplification and both
responded to cetuximab therapy. Although the number of patients
was too low for any conclusion, the level of MET gene gain
observed in our study population was lower than reported in a
previous study conducted on cell lines and patients with acquired
resistance to anti EGFR agents (Engelman et al, 2007). Although
obtained in tissues collected before starting cetuximab therapy,
these findings suggest that only high level of MET gene gain could
be responsible for resistance, levels probably occurring only under
therapeutic pressure and rarely present in a general population of
patients unexposed to anti-EGFR agents.
IGF1R is overexpressed in 50–90% of CRC (Weber et al, 2002;
Koda et al, 2004), and preclinical studies suggested that this target
could be responsible for resistance to anti-EGFR strategies
(Chakravarti et al, 2002). In our study, IGF1R expression was
not associated with cetuximab resistance, probably because the
IGF1R pathway did not affect the antiproliferative activity of
cetuximab, as recently observed in a lung cancer model (Morgillo
et al, 2007). In the study conducted by Morgillo et al (2007) only
the treatment with gefitinib, an EGFR-TKI, but not cetuximab,
induced EGFR-IGF1R heterodimerisation and activation of IGF1R
and its downstream signalling mediators, resulting in increased
survivin expression in NSCLC cell lines with high levels of IGF1R
expression. Interestingly, IGF1R-expressing patients had longer
survival than IGF1R negative. A similar pattern has been observed
in other malignancies such as non-small cell lung cancer or soft
tissue sarcomas (Ahle ´n et al, 2005; Cappuzzo et al, 2006), whereas
the opposite situation was found in other malignancies such as
uveal melanoma and breast cancer (Turner et al, 1997; All-Ericsson
et al, 2002). The significant association with survival is of
particular relevance and merits further investigations, considering
the number of strategies interfering with the IGF1R pathway under
evaluation in solid cancers, including CRC. In our study, no
patient had IGF1R gene amplification and the level of IGF1R gene
gain was very low in the whole analysed population, suggesting
that such event is not involved in primary resistance. Moreover, no
association was found between IGF1R gene and protein expression,
suggesting post-transcriptional events could also interfere with the
gene function.
To conclude, the present study showed that presence of KRAS
mutations represents the strongest predictor for cetuximab failure
in EGFR FISH-positive CRC patients. The rarity of MET and IGF1R
gene amplification suggest that such biological events play a
limited role in primary resistance to anti-EGFR agents. The impact
of BRAF mutation on cetuximab resistance as well as the potential
prognostic implications of IGF1R expression requires further
investigation.
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